达格列净治疗胶原纤维性肾小球病。

IF 1.1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2025-09-01 Epub Date: 2025-02-18 DOI:10.2169/internalmedicine.4952-24

Enyu Imai, Atsuhiro Imai, Masaaki Izumi, Jun Nakazawa, Hideki Fujii, Shinichi Nishi

{"title":"达格列净治疗胶原纤维性肾小球病。","authors":"Enyu Imai, Atsuhiro Imai, Masaaki Izumi, Jun Nakazawa, Hideki Fujii, Shinichi Nishi","doi":"10.2169/internalmedicine.4952-24","DOIUrl":null,"url":null,"abstract":"Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet been reported. A 45-year-old Japanese woman was treated daily with 10 mg dapagliflozin. Her eGFR slope improved from -3.61 mL/min/1.73 m2/year over 4 years before treatment to 0.11 mL/min/1.73 m2/year after 3 years of treatment. Additionally, her nephrotic-range proteinuria, initially exceeding 4 g/gCr, decreased to <2 g/gCr after dapagliflozin treatment. To our knowledge, this is the first documented case of effective treatment for collagenofibrotic glomerulopathy.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2615-2618"},"PeriodicalIF":1.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463412/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dapagliflozin for the Treatment of Collagenofibrotic Glomerulopathy.\",\"authors\":\"Enyu Imai, Atsuhiro Imai, Masaaki Izumi, Jun Nakazawa, Hideki Fujii, Shinichi Nishi\",\"doi\":\"10.2169/internalmedicine.4952-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet been reported. A 45-year-old Japanese woman was treated daily with 10 mg dapagliflozin. Her eGFR slope improved from -3.61 mL/min/1.73 m2/year over 4 years before treatment to 0.11 mL/min/1.73 m2/year after 3 years of treatment. Additionally, her nephrotic-range proteinuria, initially exceeding 4 g/gCr, decreased to <2 g/gCr after dapagliflozin treatment. To our knowledge, this is the first documented case of effective treatment for collagenofibrotic glomerulopathy.\",\"PeriodicalId\":13719,\"journal\":{\"name\":\"Internal Medicine\",\"volume\":\" \",\"pages\":\"2615-2618\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463412/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.4952-24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4952-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

胶原纤维性肾小球病是一种罕见的、无法治愈的肾脏疾病，其特征是严重的蛋白尿和广泛的III型胶原沉积在系膜和内皮下间隙。迄今为止，尚无有效治疗方法的报道。一名45岁的日本妇女每天服用10mg达格列净。她的eGFR斜率从治疗前4年的-3.61 mL/min/1.73 m2/年改善到治疗3年后的0.11 mL/min/1.73 m2/年。此外，她的肾范围蛋白尿，最初超过4 g/gCr，下降到

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dapagliflozin for the Treatment of Collagenofibrotic Glomerulopathy.

Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet been reported. A 45-year-old Japanese woman was treated daily with 10 mg dapagliflozin. Her eGFR slope improved from -3.61 mL/min/1.73 m²/year over 4 years before treatment to 0.11 mL/min/1.73 m²/year after 3 years of treatment. Additionally, her nephrotic-range proteinuria, initially exceeding 4 g/gCr, decreased to <2 g/gCr after dapagliflozin treatment. To our knowledge, this is the first documented case of effective treatment for collagenofibrotic glomerulopathy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.